Northeast Investment Management Sells 36,041 Shares of Kenvue Inc. (NYSE:KVUE)

Northeast Investment Management decreased its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 27.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 97,454 shares of the company's stock after selling 36,041 shares during the period. Northeast Investment Management's holdings in Kenvue were worth $2,254,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD grew its stake in shares of Kenvue by 23.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company's stock valued at $2,887,773,000 after acquiring an additional 25,238,112 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Kenvue by 12.0% in the 1st quarter. Vanguard Group Inc. now owns 166,789,085 shares of the company's stock valued at $3,579,294,000 after purchasing an additional 17,908,497 shares in the last quarter. Van ECK Associates Corp boosted its stake in shares of Kenvue by 110.9% during the 2nd quarter. Van ECK Associates Corp now owns 20,510,427 shares of the company's stock valued at $372,880,000 after buying an additional 10,783,258 shares during the last quarter. Clearbridge Investments LLC increased its stake in shares of Kenvue by 16,051.1% in the first quarter. Clearbridge Investments LLC now owns 9,813,597 shares of the company's stock worth $210,600,000 after buying an additional 9,752,836 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Kenvue by 21.0% in the second quarter. Bank of New York Mellon Corp now owns 43,444,085 shares of the company's stock worth $789,813,000 after buying an additional 7,546,362 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Analysts Set New Price Targets

KVUE has been the subject of several recent analyst reports. Royal Bank of Canada lowered shares of Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 price objective for the company. in a report on Tuesday, September 24th. Bank of America upped their price objective on Kenvue from $24.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, October 22nd. Piper Sandler lifted their target price on Kenvue from $20.00 to $21.00 and gave the stock a "neutral" rating in a research report on Monday, September 23rd. UBS Group boosted their price target on Kenvue from $20.00 to $22.00 and gave the company a "neutral" rating in a report on Wednesday, August 7th. Finally, Jefferies Financial Group assumed coverage on Kenvue in a research note on Tuesday, September 24th. They set a "buy" rating and a $27.00 price objective on the stock. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $22.64.

Kenvue Trading Up 1.4 %

Shares of Kenvue stock traded up $0.31 during trading on Monday, hitting $23.04. The stock had a trading volume of 17,341,816 shares, compared to its average volume of 18,107,514. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $44.13 billion, a PE ratio of 39.19, a P/E/G ratio of 3.00 and a beta of 1.35. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $23.55. The stock has a 50 day simple moving average of $22.53 and a 200 day simple moving average of $20.42.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of $0.28 by $0.04. The firm had revenue of $4 billion during the quarter, compared to analyst estimates of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The business's quarterly revenue was down .3% compared to the same quarter last year. During the same period last year, the company posted $0.32 EPS. On average, research analysts expect that Kenvue Inc. will post 1.08 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be given a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a yield of 3.56%. Kenvue's payout ratio is 141.38%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.